Related Experiment Video
Updated: Jul 11, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target
Jane E Rogers1, Kohei Yamashita2, Matheus Sewastjanow-Silva2
1Pharmacy Clinical Programs, U.T. M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Human epidermal growth factor receptor-2 (HER2) is a well-known cancer target. Many HER2-targeted agents are marketed and being investigated. Unfortunately, these therapies lack consistent responses and outcomes amongst different tumors. Questions remain as to why HER2 biology is different in different tumor types. Gastric adenocarcinomas (GACs) demonstrate both intra- and inter-tumor HER2 expression heterogeneity and show discordance amongst primary and metastatic disease sites. This creates barriers in determining HER2 agents' effectiveness and contributes to the failure of some HER2-targeted agents in the treatment of HER2-positive advanced GACs. Trastuzumab deruxtecan, an antibody drug conjugate of trastuzumab with a topoisomerase inhibitor, was recently approved for the treatment of refractory HER2-positive advanced GAC patients. There are exciting and newer therapies under investigation. Examining resistance patterns (both adaptive and acquired) along with establishing a better understanding of the intra- and inter-tumor heterogeneity is necessary to ensure successful progress. Here we review the current status of HER2-targeted therapy in GACs. We additionally review newer therapies under investigation and their potential role in HER2 GACs.
Insights
Human epidermal growth factor receptor-2 (HER2) targeted therapies show varied effectiveness in gastric cancers due to tumor heterogeneity. Understanding resistance is key for developing new HER2-targeted treatments.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- Human epidermal growth factor receptor-2 (HER2) is a critical target in cancer therapy.
- HER2-targeted agents exhibit inconsistent efficacy across diverse tumor types.
- Gastric adenocarcinomas (GACs) display significant intra- and inter-tumor HER2 expression heterogeneity.
Purpose of the Study:
- To review the current landscape of HER2-targeted therapies in GACs.
- To examine the challenges posed by HER2 heterogeneity and resistance in GAC treatment.
- To discuss emerging therapies and their potential impact on HER2-positive GACs.
Main Methods:
- Literature review of HER2-targeted therapies in GACs.
- Analysis of studies addressing HER2 heterogeneity and resistance mechanisms.
- Review of ongoing clinical investigations for novel HER2-directed agents.
Main Results:
- HER2 expression heterogeneity complicates treatment decisions and outcomes in GACs.
- Discordance in HER2 status between primary and metastatic sites affects therapeutic response.
- Trastuzumab deruxtecan offers a new option for refractory HER2-positive advanced GAC.
Conclusions:
- A deeper understanding of HER2 heterogeneity and resistance patterns is crucial for advancing GAC treatment.
- Further investigation into novel HER2-targeted agents is warranted.
- Personalized therapeutic strategies are needed to overcome treatment barriers in HER2-positive GACs.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...